Beta Bionics(BBNX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Beta Bionics
BBNX.US
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc.
1.349 T
BBNX.USMarket value -Rank by Market Cap -/-

Financial Score

24/01/2026 Update
C
Health Care EquipmentIndustry
Industry Ranking63/176
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-236.20%E
    • Profit Margin-87.89%E
    • Gross Margin55.48%B
  • Growth ScoreA
    • Revenue YoY67.01%A
    • Net Profit YoY-40.27%D
    • Total Assets YoY240.47%A
    • Net Assets YoY796.85%A
  • Cash ScoreB
    • Cash Flow Margin-113.78%D
    • OCF YoY67.01%A
  • Operating ScoreC
    • Turnover0.41C
  • Debt ScoreA
    • Gearing Ratio10.69%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    19:29 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX

    Pomerantz Law Firm is investigating claims on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX) regarding potential securities fraud or unlawful business practices by the company and its officers. Following a report of a 36% year-over-year increase in new patient starts, Beta Bionics' stock price fell by 37.03% to $20.15 per share. Investors are encouraged to contact Pomerantz for more information about joining the class action.

    prnewswire·
    US
    BBNX
    -3.30%
    prnewswire·
    US
    BBNX
    -3.30%

    Biotics AI, Battlefield 2023, gains FDA approval for its AI-powered fetal ultrasound product

    Biotics AI, winner of TechCrunch Disrupt Battlefield 2023, has received FDA approval for its AI-powered fetal ultrasound product designed to detect abnormalities. Founded by Robhy Bustami, the technology aims to improve prenatal outcomes, particularly for high-risk demographics. The product underwent nearly three years of FDA testing, emphasizing the importance of aligning engineering and regulatory processes. With FDA clearance, Biotics AI plans to scale its technology across health systems and enhance features for fetal medicine and reproductive health.

    TechCrunch·
    US
    BBNX
    -3.30%
    TechCrunch·
    US
    BBNX
    -3.30%

    Beta Bionics Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results

    Beta Bionics Inc. will announce its fourth quarter and full year 2025 financial results on February 17, 2026, after market close. A conference call and webcast will follow at 4:30 pm ET to discuss the company's performance. The webcast can be accessed in the 'Investors-Events & Presentations' section.

    Reuters·
    US
    BBNX
    -3.30%
    Reuters·
    US
    BBNX
    -3.30%

    01:10 ET BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm

    The Schall Law Firm is investigating claims on behalf of Beta Bionics, Inc. (NASDAQ: BBNX) investors for potential violations of securities laws. The investigation centers on whether the company made false or misleading statements, particularly after it announced on January 8, 2026, a lower-than-expected number of patient starts, leading to a 37% drop in share prices. Shareholders who suffered losses are encouraged to participate in the investigation and can contact the firm for more information.

    prnewswire·
    US
    BBNX
    -3.30%
    prnewswire·
    US
    BBNX
    -3.30%

    Beta Bionics (NASDAQ:BBNX) Shares Down 9.2% Following Analyst Downgrade

    Beta Bionics (NASDAQ:BBNX) shares fell 9.2% after Wall Street Zen downgraded the stock from hold to sell. The stock traded as low as $17.83 and closed at $18.28, with a significant drop in trading volume. Despite this, several analysts have set higher price targets, with Goldman Sachs raising theirs from $26 to $33. Insider selling has also been reported, with key executives reducing their holdings. The company reported a quarterly EPS of ($0.33), exceeding estimates, and had revenue of $27.25 million, above expectations.

    Market Beat·
    US
    BBNX
    -3.30%
    Market Beat·
    US
    BBNX
    -3.30%
    © 2026 Longbridge｜Disclaimer